KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Receivables - Other: 2011-2025

Historic Receivables - Other for Travere Therapeutics (TVTX) over the last 3 years, with Sep 2025 value amounting to $1.5 million.

  • Travere Therapeutics' Receivables - Other fell 40.00% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 40.00%. This contributed to the annual value of $2.3 million for FY2024, which is 50.00% down from last year.
  • Latest data reveals that Travere Therapeutics reported Receivables - Other of $1.5 million as of Q3 2025, which was down 0.00% from $1.5 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Receivables - Other high stood at $4.6 million for Q4 2023, and its period low was $900,000 during Q4 2021.
  • Moreover, its 3-year median value for Receivables - Other was $2.5 million (2024), whereas its average is $2.7 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first spiked by 142.11% in 2023, then slumped by 50.00% in 2024.
  • Over the past 5 years, Travere Therapeutics' Receivables - Other (Quarterly) stood at $900,000 in 2021, then surged by 111.11% to $1.9 million in 2022, then spiked by 142.11% to $4.6 million in 2023, then tumbled by 50.00% to $2.3 million in 2024, then slumped by 40.00% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $2.1 million during Q1 2025.